ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2017
Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Association between density of tumor-infiltrating lymphocytes and prognoses of patients with gastric cancer.Medicine · 2018Pooled it
- The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis.PloS one · 2017Pooled it
- Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.Oral health & preventive dentistry · 2026Article
- NOVA1 Activation Modulates the Tumor Immune Microenvironment through STING Phosphorylation in Head and Neck Squamous Cell Carcinoma.Cancer research and treatment · 2026Article
- Stemness-based gastric cancer classification by machine learning for precision diagnosis and treatment of gastric cancer.Journal of gastrointestinal oncology · 2025Article
- Hotspots and frontiers of the relationship between gastric cancer and cancer-associated fibroblasts: a bibliometric analysis.Frontiers in oncology · 2025Article
- Prognostic alternative mRNA splicing in lung adenocarcinoma.Frontiers in oncology · 2025Article
- The splicing machinery is dysregulated and represents a therapeutic vulnerability in breast cancer.Cellular and molecular life sciences : CMLS · 2024Article
- NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.BMC cancer · 2024Article
- Uncovering the ceRNA Network Related to the Prognosis of Stomach Adenocarcinoma Among 898 Patient Samples.Biochemical genetics · 2024Article
- Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.International journal of molecular sciences · 2024Review
- Bioinformatics analysis of the prognostic role of alternative splicing data in lung adenocarcinoma.Journal of thoracic disease · 2024Article
- CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage.Oncoimmunology · 2024Article
- Identifying potential pathogenesis and immune infiltration in diabetic foot ulcers using bioinformatics and in vitro analyses.BMC medical genomics · 2023Article
- The role of alternative pre-mRNA splicing in cancer progression.Cancer cell international · 2023Review
- Genome-wide identification of alternative splicing and splicing regulated in immune infiltration in osteosarcoma patients.Frontiers in genetics · 2023Article
- A comprehensive characterization of alternative splicing events related to prognosis and the tumor microenvironment in lung adenocarcinoma.Annals of translational medicine · 2022Article
- Immunological significance of alternative splicing prognostic signatures for bladder cancer.Heliyon · 2022Article
- Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.Journal of immunology research · 2022Article
- Exploring Potential Regulatory Anesthetic Drugs Based on RNA Binding Protein and Constructing CESC Prognosis Model: A Study Based on TCGA Database.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neuronal splicing factor neuro-oncological ventral antigen 1 (NOVA1) is enriched in normal fibroblasts. Stromal spindle cells such as fibroblasts are major components of tissue inflammation and tertiary lymphoid structures within the microenvironment that contribute to the survival and growth of cancer cells. In the present study, we investigated changes of NOVA1 expression in tertiary lymphoid structures in early and advanced gastric cancer microenvironments in terms of tumor progression and immune regulation.
methodsUsing immunohistochemistry, we analyzed NOVA1 expression in tumor cells, T cells, and stromal spindle cells as well as infiltrating densities of CD3
resultsSuppressed NOVA1 expression in tumor cells, T cells, and stromal spindle cells was closely related to decreased infiltration of FOXP3
conclusionsNOVA1 suppression was frequently noted in the gastric cancer microenvironment, and attenuated NOVA1 expression in tumor cells was associated with tumor progression and poor prognosis. This finding seems to be related to immune dysfunction through changes in the immune cell composition of T cells and macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.